
Correction**Correction: Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors**

In this article (Clin Cancer Res 2010;16:5862–72), which was published in the December 1, 2010 issue of *Clinical Cancer Research* (1), an affiliation for Prof. Mario R. Sertoli was missing. The correct affiliations for Prof. Sertoli are Department of Medical Oncology, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy and Department of Oncology, Biology, and Genetics, University of Genova, Genova, Italy.

Reference

1. Del Vecchio M, Mortarini R, Canova S, Di Guardo L, Pimpinelli N, Sertoli MR, et al. Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors. Clin Cancer Res 2010;16:5862–72.

Published Online First January 25, 2011.

©2011 American Association for Cancer Research.

doi: 10.1158/1078-0432.CCR-10-3193

Clinical Cancer Research

Correction: Bevacizumab plus Fotemustine as First-line Treatment in Metastatic Melanoma Patients: Clinical Activity and Modulation of Angiogenesis and Lymphangiogenesis Factors

Clin Cancer Res 2011;17:630. Published OnlineFirst January 25, 2011.

Updated version Access the most recent version of this article at:
doi:[10.1158/1078-0432.CCR-10-3193](https://doi.org/10.1158/1078-0432.CCR-10-3193)

Cited articles This article cites 1 articles, 1 of which you can access for free at:
<http://clincancerres.aacrjournals.org/content/17/3/630.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://clincancerres.aacrjournals.org/content/17/3/630>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.